Compare Illumina, Inc. (ILMN) vs US Bancorp (USB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs US Bancorp — how do they compare? Illumina, Inc. trades at $278.1 (market cap $39.95B), while US Bancorp trades at $57.1 (market cap $88.86B). The key difference: US Bancorp is far larger — about 2.2× Illumina, Inc.'s market cap, and US Bancorp pays a 3.79% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and US Bancorp for 97 Days on average.
| ILMN | USB | |
|---|---|---|
Market Cap | $39.95B | $88.86B |
Volume | 3,169,503 | 8,869,993 |
Sector | Health | Financials |
52-Week High | $293.69 | $65.42 |
52-Week Low | $91.00 | $45.28 |
Typical Hold Time | 83 Days | 97 Days |
Enterprise Value | $41.31B | $118.35B |
Dividend Yield | — | 3.79% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
U.S. Bancorp (USB) trades at $56.81, up 1.14% today, but technical indicators are bearish with moving averages signaling a downtrend. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Fundamentals show strong profitability with a 27.61% net income margin and a modest P/E of 11.38. The company recently raised its dividend by 3.8% to $0.54 per share, reflecting confidence in its financial health.
The outlook is mixed: analyst consensus is bullish with a $69.94 price target, but near-term technical weakness and macroeconomic sensitivity pose risks. Upside potential hinges on continued earnings outperformance and stable interest rates, while downside risks include regulatory changes and economic volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →
